Zydus Cadila on November 20, 2015 launched Tenglyn (teneligliptin 20 mg) tablet, which belongs to a new class of oral anti-diabetic agents - gliptins. With an aim to make this important therapy affordable and accessible to diabetic patients, Tenglyn is being priced at just Rs 7 per tablet which is almost 1/6th the price at which the gliptins were initially launched in India, claims Zydus Cadila.
Gliptins have shown promise in achieving glycemic control without deteriorating beta cell function and is one of the most recent advancements in diabetes care and management. Research in the field of anti-diabetic therapy seeks to address the problems of hypoglycemia, GI side effects, lactic acidosis, weight gain, CV risks, etc, which pose a major challenge in the treatment of diabetes.
Dr Sharvil Patel, deputy managing director, Zydus Cadila, said, “At Zydus, our endeavour has been to bring new therapies and innovations that address the two primary challenges in India of accessibility and affordability. Diabetes, as we know is becoming a major health burden globally. We remain committed to this fight against diabetes and with Tenglyn we provide patients suffering from diabetes access to this advanced treatment at the most affordable cost.”
The group had earlier launched Lipaglyn (saroglitazar), India's first NCE which is a breakthrough therapy in the treatment of diabetic dyslipidemia and hypertriglyceridemia.
Gliptins have shown promise in achieving glycemic control without deteriorating beta cell function and is one of the most recent advancements in diabetes care and management. Research in the field of anti-diabetic therapy seeks to address the problems of hypoglycemia, GI side effects, lactic acidosis, weight gain, CV risks, etc, which pose a major challenge in the treatment of diabetes.
Dr Sharvil Patel, deputy managing director, Zydus Cadila, said, “At Zydus, our endeavour has been to bring new therapies and innovations that address the two primary challenges in India of accessibility and affordability. Diabetes, as we know is becoming a major health burden globally. We remain committed to this fight against diabetes and with Tenglyn we provide patients suffering from diabetes access to this advanced treatment at the most affordable cost.”
The group had earlier launched Lipaglyn (saroglitazar), India's first NCE which is a breakthrough therapy in the treatment of diabetic dyslipidemia and hypertriglyceridemia.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%